Leukaemias

	08/17/2009	Questioning Clinical Assumptions in Accelerated-Phase and Blast-Crisis CML
	08/17/2009	How Can We Clarify Treatment Approaches in High-Risk CML?
	08/17/2009	How Can We Improve Treatment & Outcome in Blast-Crisis CML?
	08/05/2009	Prophylaxis and Management of Invasive Fungal Infections in Older Patients with Acute Myelogenous Leukemia
	03/20/2009	Bone Marrow Failure Syndromes Optimizing Outcomes Worldwide through Disease Understanding
	03/03/2009	Exploring New Trends in MDS & AML: From Clinical Data in Poor-Prognosis Patients to Mechanisms of Novel Agents
	03/03/2009	Interpreting New Findings on Epigenetic Changes in MDS and AML-What Impact Will They Have on Treatment?
	03/03/2009	Do Modified Treatment and Novel Therapies Augment Clinical Benefit in AML?
	03/03/2009	Crafting an Individualized Approach to MDS Therapy: New Data on Prognostic Models and Management of Higher Risk Disease
	02/16/2009	Hematology Data Update From San Francisco: Emerging Clinical Trends Across Malignant Settings
	08/25/2008	Clinical Updates in Hematology: Is More Effective Therapy Possible in Lymphoma and Leukemia?
	07/17/2008	Defining Resistance in Chronic Myeloid Leukemia (CML)
	07/17/2008	How to Incorporate Molecular Monitoring Into the Clinical Management of Chronic Myeloid Leukemia (CML)
	07/17/2008	Tailored Treatments for Patients With Chronic Myelogenous Leukemia (CML): Are We There Yet?
	03/24/2008	New Classification Systems and Therapies Instigate Evolving Diagnostic and Treatment Models of MDS
	02/14/2008	CML and Ph+ ALL: Tyrosine Kinase Inhibitors Improve Outcomes But Resistance Remains a Concern
	02/14/2008	Novel Targeted Agents Expand Options for Patients Resistant to First-Line CML Therapy
	02/14/2008	Targeted Agents Showing Promise in Imatinib-Resistant Ph+ ALL